These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 20649573

  • 1. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.
    Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC, Fagan P, Baccei CS, Santini AM, Hutchinson JH, Seiders TJ, Parr TA, Prasit P, Evans JF, Lorrain DS.
    Br J Pharmacol; 2010 Aug; 160(7):1699-713. PubMed ID: 20649573
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
    Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, Lee C, Parr TA, Roppe JR, Seiders TJ, Ziff J, Prasit P, Hutchinson JH, Evans JF, Lorrain DS.
    J Pharmacol Exp Ther; 2011 Mar; 336(3):693-700. PubMed ID: 21159750
    [Abstract] [Full Text] [Related]

  • 3. AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin.
    Cai J, Wei J, Li S, Suber T, Zhao J.
    Mediators Inflamm; 2017 Mar; 2017():6893560. PubMed ID: 28348461
    [Abstract] [Full Text] [Related]

  • 4. Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice.
    Huang LS, Fu P, Patel P, Harijith A, Sun T, Zhao Y, Garcia JG, Chun J, Natarajan V.
    Am J Respir Cell Mol Biol; 2013 Dec; 49(6):912-22. PubMed ID: 23808384
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury.
    Funke M, Zhao Z, Xu Y, Chun J, Tager AM.
    Am J Respir Cell Mol Biol; 2012 Mar; 46(3):355-64. PubMed ID: 22021336
    [Abstract] [Full Text] [Related]

  • 7. Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis.
    Cicko S, Grimm M, Ayata K, Beckert J, Meyer A, Hossfeld M, Zissel G, Idzko M, Müller T.
    Respir Res; 2015 Sep 15; 16(1):105. PubMed ID: 26369416
    [Abstract] [Full Text] [Related]

  • 8. Megakaryoblastic leukemia-1 is required for the development of bleomycin-induced pulmonary fibrosis.
    Bernau K, Ngam C, Torr EE, Acton B, Kach J, Dulin NO, Sandbo N.
    Respir Res; 2015 Mar 27; 16(1):45. PubMed ID: 25885656
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Regulation of silicosis formation by lysophosphatidic acid and its receptors.
    Cong C, Mao L, Zhang Y, Zhao Z, Xu X, Zhao J.
    Exp Lung Res; 2014 Sep 27; 40(7):317-26. PubMed ID: 24926730
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
    Pini A, Shemesh R, Samuel CS, Bathgate RA, Zauberman A, Hermesh C, Wool A, Bani D, Rotman G.
    J Pharmacol Exp Ther; 2010 Dec 27; 335(3):589-99. PubMed ID: 20826567
    [Abstract] [Full Text] [Related]

  • 13. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen deposition.
    Lu GX, Bian DF, Ji Y, Guo JM, Wei ZF, Jiang SD, Xia YF, Dai Y.
    Phytother Res; 2014 Aug 27; 28(8):1224-31. PubMed ID: 24458872
    [Abstract] [Full Text] [Related]

  • 14. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
    Ohashi T, Yamamoto T.
    Exp Dermatol; 2015 Sep 27; 24(9):698-702. PubMed ID: 25959255
    [Abstract] [Full Text] [Related]

  • 15. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE, Berdyshev E, Bain G, Castelino FV, Shea BS, Probst CK, Fontaine BA, Bronova I, Goulet L, Lagares D, Ahluwalia N, Knipe RS, Natarajan V, Tager AM.
    FASEB J; 2016 Jun 27; 30(6):2435-50. PubMed ID: 27006447
    [Abstract] [Full Text] [Related]

  • 16. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.
    Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM.
    Arthritis Rheum; 2011 May 27; 63(5):1405-15. PubMed ID: 21305523
    [Abstract] [Full Text] [Related]

  • 17. Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis.
    Ding L, Dolgachev V, Wu Z, Liu T, Nakashima T, Wu Z, Ullenbruch M, Lukacs NW, Chen Z, Phan SH.
    J Pathol; 2013 Jun 27; 230(2):205-14. PubMed ID: 23401096
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.